Poseida Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Poseida Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q3 2024.
  • Poseida Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was $20.2M.
  • Poseida Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$60.8M, a 53.8% increase year-over-year.
  • Poseida Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$123M, a 92.9% decline from 2022.
  • Poseida Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$64M, a 48.8% increase from 2021.
  • Poseida Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$125M, a 3.7% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$60.8M $20.2M +$52M Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$113M -$31.4M -$3.92M -14.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$109M -$24.3M +$14.6M +37.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$123M -$25.3M +$7.97M +23.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$131M -$31.8M -$102M -145% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$29.2M -$27.5M +$15.6M +36.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$44.8M -$38.8M +$19.2M +33.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$64M -$33.3M -$34.8M -2368% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$29.2M $70.4M +$113M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$142M -$43M +$2.67M +5.84% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$145M -$58.1M -$19.7M -51.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$125M $1.47M +$37.6M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$163M -$42.4M -$8.01M -23.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$155M -$45.7M -$15.3M -50.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$139M -$38.3M -$9.53M -33.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$130M -$36.1M -$12.5M -53.1% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$117M -$34.4M -$13.5M -64.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$104M -$30.4M -$1.8M -6.29% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-09
Q1 2020 -$102M -$28.8M -$15.5M -116% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-09
Q4 2019 -$86.5M -$23.6M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$21M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$28.6M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 -$13.3M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.